Jenoptik (JEN) Q4 2024 earnings summary

Executive summary

• Achieved robust single-digit organic revenue growth (~5%) and EBITDA margin just below 20% in 2024, meeting guidance despite a challenging market and declining order intake.

• Order intake declined by 6% year-over-year, mainly due to weakness in automotive, life science, medical technology, and non-photonic segments.

• Organizational realignment completed, now structured around four core markets, with a leaner structure for efficiency.

• Completed construction of high-tech Dresden factory, enhancing production capacity.

• Long-term growth prospects remain intact, but 2025 is viewed as a transition year with high uncertainty.

Financial highlights

• Revenue rose 4.7% year-over-year to €1,115.8 million, with all divisions contributing; EBITDA increased 5.7% to €221.5 million.

• Earnings per share reached €1.62, up nearly 28% year-over-year; EBIT margin improved to 13.1% from 11.5%.

• Net debt reduced to €395.5 million (from €423.1 million); leverage ratio improved to 1.8x.

• Free cash flow before interest and tax was €102.9 million, down from €127.3 million due to prior-year real estate disposal.

• ROCE increased to 10.8% (prior year 9.6%).

Outlook and guidance

• 2025 revenue expected to remain around 2024 levels (±5%), with EBITDA margin guidance of 18–21%.

• Capital expenditures to decrease significantly in 2025, moving toward maintenance levels (5–6% of sales).

• High uncertainty persists due to geopolitical tensions, tariffs, and market volatility; guidance corridor remains broad.

• Anticipates upturn in semiconductor equipment industry in H2 2025, assuming no further macro deterioration.